Overview
Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization. The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence. In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. Clorazepate and its active metabolite, nordiazepam, are present in breast milk.
Indication
Clorazepate is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. It is also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
Associated Conditions
- Acute Alcohol Withdrawal
- Anxiety Acute
- Generalized Anxiety Disorder
- Partial-Onset Seizures
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2021/01/27 | Phase 3 | Terminated | |||
2008/10/20 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Apotex Corp. | 60505-4756 | ORAL | 15 mg in 1 mg | 8/24/2023 | |
Aurolife Pharma LLC | 13107-282 | ORAL | 3.75 mg in 1 1 | 1/20/2024 | |
Contract Pharmacy Services-PA | 67046-907 | ORAL | 15 mg in 1 1 | 9/28/2017 | |
Taro Pharmaceuticals U.S.A., Inc. | 51672-4044 | ORAL | 15 mg in 1 1 | 11/9/2023 | |
Ranbaxy Pharmaceuticals Inc. | 63304-553 | ORAL | 7.5 mg in 1 1 | 9/12/2012 | |
Apotex Corp. | 60505-4755 | ORAL | 7.5 mg in 1 mg | 8/24/2023 | |
Bryant Ranch Prepack | 72162-2100 | ORAL | 15 mg in 1 1 | 9/25/2023 | |
PD-Rx Pharmaceuticals, Inc. | 43063-893 | ORAL | 15 mg in 1 1 | 9/27/2023 | |
Taro Pharmaceuticals U.S.A., Inc. | 51672-4042 | ORAL | 3.75 mg in 1 1 | 11/9/2023 | |
NORTHSTAR RX LLC | 72603-112 | ORAL | 3.75 mg in 1 1 | 11/1/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
TRANXENE CAP 3.75MG | ABBOTT LABORATORIES, LIMITED | 00264938 | Capsule - Oral | 3.75 MG | 12/31/1973 |
CLORAZEPATE | aa pharma inc | 00860689 | Capsule - Oral | 3.75 MG | 12/31/1990 |
CLORAZEPATE | aa pharma inc | 00860697 | Capsule - Oral | 15 MG | 12/31/1990 |
CLORAZEPATE | aa pharma inc | 00860700 | Capsule - Oral | 7.5 MG | 12/31/1990 |
NOVO-CLOPATE CAP 7.5MG | novopharm limited | 00628204 | Capsule - Oral | 7.5 MG | 12/31/1984 |
TRANXENE CAP 7.5MG | ABBOTT LABORATORIES, LIMITED | 00264946 | Capsule - Oral | 7.5 MG / CAP | 12/31/1976 |
TRANXENE CAP 15MG | ABBOTT LABORATORIES, LIMITED | 00264911 | Capsule - Oral | 15 MG | 12/31/1973 |
NOVO-CLOPATE CAP 3.75MG | novopharm limited | 00628190 | Capsule - Oral | 3.75 MG | 12/31/1984 |
NOVO-CLOPATE CAP 15MG | novopharm limited | 00628212 | Capsule - Oral | 15 MG | 12/31/1984 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.